We’re privileged to have earned the trust of so many world-leading researchers who recognize the value of centralization and have leveraged ERT’s scientific, technological and operational expertise to uncover and address potential patient safety issues during clinical development.”
PHILADELPHIA (PRWEB) November 20, 2019
ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced it has reached a significant milestone: Global biopharmaceutical companies have relied on ERT’s centralized cardiac safety solution to assess the safety of their new medical compounds in more than 10,000 clinical studies across all phases of clinical development.
“It’s truly an honor to support our customers and to deliver the highly precise cardiac safety data they need to ensure patient safety,” said James Corrigan, President and CEO, ERT. “We’re privileged to have earned the trust of so many world-leading researchers who recognize the value of centralization and have leveraged ERT’s scientific, technological and operational expertise to uncover and address potential patient safety issues during clinical development.”
An industry leader, ERT has a rich history of innovation in cardiac safety assessment, including pioneering research that led to revised ICH E14 regulatory guidance enabling clinical trial sponsors to better prioritize their pipelines by characterizing QT earlier in clinical development. And, its proven, centralized approach reduces improper inclusion and exclusion decisions, ensuring that only the correct patients participate in clinical trials, further ensuring their safety while accelerating study timelines.
“Reaching the 10,000th study milestone is a testament to the dedication of our entire cardiac safety team,” said Ellen Street, Executive Vice President, Cardiac Safety, ERT. “Their passion for helping our customers bring new medical treatments to patients in need has enabled us to continue delivering cardiac safety solutions that are not only technologically advanced, but most importantly, ensure patient safety.”
For more information on ERT’s suite of cardiac solutions, visit ert.com/cardiac-safety.
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.
Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. Since 2013, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.